Recentin
Term · Oncology and biomedicine · MLC-T-ONC-007244
A substance being studied in the treatment of some types of cancer. Recentin may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called AZD2171 and cediranib maleate.
| Identifier | MLC-T-ONC-007244 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | AZD2171; cediranib maleate |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-007244",
"term": "Recentin",
"field": "Oncology and biomedicine",
"definition": "A substance being studied in the treatment of some types of cancer. Recentin may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called AZD2171 and cediranib maleate.",
"synonyms": [
"AZD2171",
"cediranib maleate"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/recentin/"
}
Record 14,113 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.